A recombinant adenovirus vector tumor vaccine and a preparation method and application thereof

By using a recombinant adenovirus vector to encode KRAS antigen peptides and fusion proteins, and combining them with the mucosal immune pathway, the lack of specificity of existing tumor vaccines in lung cancer treatment has been solved, achieving highly efficient killing and prevention of Kras-driven tumors.

CN122146786APending Publication Date: 2026-06-05BRITIE BIOTECH CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
BRITIE BIOTECH CO LTD
Filing Date
2025-12-02
Publication Date
2026-06-05

AI Technical Summary

Technical Problem

Existing cancer vaccines suffer from insufficient specificity and tolerability issues when targeting tumor-associated antigens or tumor-specific antigens, resulting in weak immune responses and making it difficult to effectively prevent and treat Kras-driven cancers such as lung cancer.

Method used

Using a recombinant adenovirus vector encoding the antigenic peptide epitope of the KRAS protein, combined with fusion proteins that promote and enhance cellular immune antigen presentation, such as LC3B, IFN-γ, IL12, GM-CSF, IL21, CCL3, and CCL5, the drug is administered via mucosal immune pathways such as nebulized inhalation to generate systemic and mucosal immune responses, thereby enhancing the ability to recognize and kill tumor cells.

Benefits of technology

It improves the killing effect on Kras-driven tumors, enhances the treatment and prevention of cancers such as lung cancer, and in particular provides a more effective anti-tumor protective immune response through the mucosal immune pathway, reducing the risk of tumor recurrence.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN122146786A_ABST
    Figure CN122146786A_ABST
Patent Text Reader

Abstract

The application discloses a recombinant adenovirus vector tumor vaccine and a preparation method and application thereof, wherein the antigen coded by the recombinant adenovirus vector tumor vaccine comprises any one or a combination of more than two antigen peptide epitopes of KRAS protein. The recombinant adenovirus vector tumor vaccine of the application codes multiple KRAS tumor-specific antigen peptides, and has a good killing effect on KRAS mutation-driven tumors, especially lung tumors. The vaccine can be inhaled in a form of atomization, injected into muscles first and then inhaled in a form of atomization, inhaled in a form of atomization first and then injected into muscles, injected into muscles, or simultaneously injected into muscles and administered in a form of atomization. After atomization, the vaccine can be inhaled through a nasal cavity or an oral cavity to reach the lungs, generate an anti-tumor protective immune response on the respiratory tract, the lungs and the whole body, and enhance the utilization rate and the treatment effect of the vaccine.
Need to check novelty before this filing date? Find Prior Art